Septerna reports Q3 2024 net loss of $20.5M; cash runway into H2 2027 after IPO

Septerna, Inc.

2024-Q3 EPS reported -$21.87 revenue$863,000

Net loss of $20.5M for Q3 2024; R&D expenses $17.8M, G&A $4.9M.
Cash, equivalents, and marketable securities $137.5M as of Sep 30, 2024; plus $302.6M net IPO proceeds in Oct 2024 extend runway into H2 2027.
Phase 1 trial of SEP-786 (oral PTH1R agonist for hypoparathyroidism) ongoing; data expected mid-2025.
SEP-631 (MRGPRX2 NAM for CSU) in IND-enabling studies; TSHR NAM program for Graves' disease progressing.
Jae Kim, M.D. appointed CMO in September 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.